CN114949326A - Medical dressing material - Google Patents
Medical dressing material Download PDFInfo
- Publication number
- CN114949326A CN114949326A CN202110420483.0A CN202110420483A CN114949326A CN 114949326 A CN114949326 A CN 114949326A CN 202110420483 A CN202110420483 A CN 202110420483A CN 114949326 A CN114949326 A CN 114949326A
- Authority
- CN
- China
- Prior art keywords
- cellulose
- medical dressing
- powder
- modified cellulose
- alkaline solution
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000463 material Substances 0.000 title claims abstract description 8
- 229920002678 cellulose Polymers 0.000 claims abstract description 74
- 239000001913 cellulose Substances 0.000 claims abstract description 74
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims abstract description 47
- 125000002091 cationic group Chemical group 0.000 claims abstract description 25
- 230000003385 bacteriostatic effect Effects 0.000 claims abstract description 22
- 239000012670 alkaline solution Substances 0.000 claims description 23
- 238000006467 substitution reaction Methods 0.000 claims description 21
- MCMNRKCIXSYSNV-UHFFFAOYSA-N Zirconium dioxide Chemical compound O=[Zr]=O MCMNRKCIXSYSNV-UHFFFAOYSA-N 0.000 claims description 18
- 150000003242 quaternary ammonium salts Chemical class 0.000 claims description 14
- 238000001238 wet grinding Methods 0.000 claims description 10
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 9
- 239000011324 bead Substances 0.000 claims description 9
- 239000000843 powder Substances 0.000 claims description 7
- 229920000742 Cotton Polymers 0.000 claims description 5
- 239000000243 solution Substances 0.000 claims description 4
- 239000007864 aqueous solution Substances 0.000 claims description 3
- 238000001035 drying Methods 0.000 claims description 3
- 230000007935 neutral effect Effects 0.000 claims description 3
- LTVDFSLWFKLJDQ-UHFFFAOYSA-N α-tocopherolquinone Chemical group CC(C)CCCC(C)CCCC(C)CCCC(C)(O)CCC1=C(C)C(=O)C(C)=C(C)C1=O LTVDFSLWFKLJDQ-UHFFFAOYSA-N 0.000 claims description 3
- 238000000227 grinding Methods 0.000 claims description 2
- 238000010438 heat treatment Methods 0.000 claims description 2
- 238000012986 modification Methods 0.000 abstract description 18
- 230000004048 modification Effects 0.000 abstract description 18
- 238000000034 method Methods 0.000 description 14
- 239000002994 raw material Substances 0.000 description 13
- 230000000052 comparative effect Effects 0.000 description 9
- 239000000126 substance Substances 0.000 description 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- 241000894006 Bacteria Species 0.000 description 4
- 238000011156 evaluation Methods 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- 238000005259 measurement Methods 0.000 description 3
- 239000003607 modifier Substances 0.000 description 3
- 239000000178 monomer Substances 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical group O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 229920001661 Chitosan Polymers 0.000 description 2
- 206010020751 Hypersensitivity Diseases 0.000 description 2
- 241000191967 Staphylococcus aureus Species 0.000 description 2
- 238000002441 X-ray diffraction Methods 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 239000012535 impurity Substances 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- JPKKMFOXWKNEEN-UHFFFAOYSA-N 2-methylcholine Chemical group CC(O)C[N+](C)(C)C JPKKMFOXWKNEEN-UHFFFAOYSA-N 0.000 description 1
- 241000193998 Streptococcus pneumoniae Species 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 125000004429 atom Chemical group 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 239000003637 basic solution Substances 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 229920005610 lignin Polymers 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000003801 milling Methods 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 239000002861 polymer material Substances 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/22—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing macromolecular materials
- A61L15/28—Polysaccharides or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/42—Use of materials characterised by their function or physical properties
- A61L15/46—Deodorants or malodour counteractants, e.g. to inhibit the formation of ammonia or bacteria
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Materials Engineering (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Materials For Medical Uses (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
A medical dressing material comprises modified cellulose having a cationic group, wherein the modified cellulose is obtained by cationizing a cellulose powder having a crystallinity of 0 to 0.5. The medical dressing including the modified cellulose provided by the present disclosure has a good bacteriostatic effect, and the cellulose powder of low crystallinity increases the modification efficiency of the cellulose powder.
Description
Technical Field
The present disclosure relates to medical dressings, and more particularly to medical dressings comprising cellulose.
Background
The polymer compound having positive charge interferes with the growth of bacteria or causes the death of bacteria, and thus can be used as a bacteriostatic product for medical treatment, such as dressing, patch, suture, and the like. The polymer material includes animal component and plant component, such as chitosan or modified cellulose. However, chitosan requires a large amount of chemical solvent for treatment and may cause allergic reactions, and the production of cellulose products is limited by its inefficient modification process. Therefore, how to improve the cellulose modification efficiency is an important development project for medical dressings.
Disclosure of Invention
The present disclosure provides a medical dressing including modified cellulose having cationic groups, which can have a good bacteriostatic effect.
According to some embodiments of the present disclosure, a medical dressing includes modified cellulose having cationic groups, wherein the modified cellulose is formed by cationizing a cellulose powder having a crystallinity of between 0 and 0.5.
In some embodiments, the degree of substitution of the cationic groups of the modified cellulose is between 0.25 and 0.6.
In some embodiments, the medical dressing has a bacteriostatic value between 85% and 100%.
In some embodiments, the cellulose powder having a crystallinity of between 0 and 0.5 is formed by wet milling a cellulose raw material in a neutral aqueous solution.
In some embodiments, the wet milling comprises milling the cellulosic feedstock with a planetary ball mill and zirconia beads, wherein the zirconia beads have a diameter between 0.2 cm and 1.0 cm.
In some embodiments, the cellulose powder is cotton powder.
In some embodiments, cationizing the cellulose powder comprises dissolving the cellulose powder in an alkaline solution, adding a quaternary ammonium salt to the alkaline solution, heating the alkaline solution, and subjecting the alkaline solution to a drying process to form the modified cellulose.
In some embodiments, the alkaline solution is a sodium hydroxide solution having a concentration between 5 wt% and 10 wt%.
In some embodiments, the concentration of the quaternary ammonium salt in the basic solution is between 6.0 wt% and 6.5 wt%.
In some embodiments, the quaternary ammonium salt is 3-chloro-2-hydroxypropyltrimethylammonium chloride.
According to the embodiments of the present disclosure, since the medical dressing of the present disclosure includes the modified cellulose having the cationic group, the medical dressing may have a good bacteriostatic effect. On the other hand, since the cellulose powder used to form the modified cellulose has low crystallinity, the modification efficiency of the cellulose powder can be increased, and the use of a modifier is reduced to reduce the modification cost.
Detailed Description
The following disclosure provides many different embodiments, or examples, for implementing different features of the claimed subject matter. Specific examples of values, acts, materials, etc., are described below to simplify the present disclosure. These are, of course, merely examples and are not intended to be limiting.
Herein, the structure of a polymer or group is sometimes represented by a bond line type (skeletton formula). This notation may omit carbon atoms, hydrogen atoms, and carbon-hydrogen bonds. The drawing is taken to refer to the atoms or atomic groups explicitly depicted in the structural formula.
The present disclosure provides a medical dressing including modified cellulose having cationic groups, which may have a good bacteriostatic effect. Since the modified cellulose is modified by the cellulose powder having a low crystallinity, the modification efficiency of the cellulose powder can be increased and the modification cost can be reduced.
The medical dressing disclosed by the invention comprises modified cellulose, wherein the modified cellulose has cationic groups, so that a good bacteriostatic effect of the medical dressing is provided. The modified cellulose is formed by subjecting cellulose powder to a modification process. More specifically, the modified cellulose is formed by cationizing cellulose powder with crystallinity between 0 and 0.5 by using a modifier. The low crystallinity of the cellulose powder can promote the chemical reaction between the cellulose powder and the modifier, thereby increasing the modification efficiency of the cellulose powder and improving the bacteriostatic effect of the medical dressing.
In some embodiments, cellulose molecules in the cellulose powder are cationized such that cationic groups can be substituted for hydroxide functional groups of the cellulose molecules, thereby forming a modified cellulose having cationic groups. Specifically, the monomer for modifying cellulose may have a structure represented by the following formula (1),
wherein R is a cationic group. In some embodiments, the cationic groups of the modified cellulose may include positively charged quaternary amine groups. For example, in the monomer of the modified cellulose represented by formula (1), R may be a 2-hydroxypropyl-N, N, N-trimethylammonium group having a cation, and the monomer thereof may have a structure as shown in the following formula (2),
in some embodiments, the modified cellulose may have a suitable degree of substitution of cationic groups such that the modified cellulose has a suitable positive charge amount. Therefore, the modified cellulose with positive charges can provide good bacteriostatic effect for the medical dressing. In some embodiments, the degree of substitution of the cationic groups of the modified cellulose may be between 0.25 and 0.6. Specifically, if the substitution degree of the cationic group is less than 0.25, an effective positive charge amount may not be provided, thereby reducing the bacteriostatic effect of the medical dressing; if the substitution degree of the cationic group is greater than 0.6, the modification cost is increased, and the bacteriostatic effect of the medical dressing material cannot be obviously increased, so that the resource waste is caused. In some embodiments, since the medical dressing comprises modified cellulose with a suitable degree of substitution, the bacteriostatic value of the medical dressing can be between 85% and 100%, and the bacteriostatic effect of the medical dressing can be expanded to one or more strains.
In some embodiments, the forming of the modified cellulose may include subjecting the cellulosic feedstock to a wet grinding process to form a cellulose powder. Thus, the crystallinity of the formed cellulose powder can be reduced, thereby increasing the modification efficiency of the cellulose powder in the subsequent modification process. Specifically, the cellulose raw material may be subjected to a wet grinding process in a neutral aqueous solution to form cellulose powder, wherein water may be used as a lubricant or the process temperature may be lowered, thereby reducing the addition of organic solvents or acid-base solutions and avoiding the residue of chemical solvents.
In some embodiments, the wet grinding process may include grinding the cellulose raw material using a planetary ball mill and zirconia beads, and the weight ratio of the zirconia beads to the cellulose raw material may be between 90 and 100. The cellulosic feedstock may be milled using zirconia beads having a suitable diameter to form a cellulosic powder having low crystallinity. For example, the zirconia beads may have a diameter of 0.2 cm to 1.0 cm, preferably 0.5 cm to 1.0 cm.
In some embodiments, the cellulosic feedstock may be selected from components having a high cellulose content, such that the resulting cellulosic powder has a low content of impurities, thereby reducing the steps of repurifying the cellulosic powder. For example, cotton may be selected as the cellulose raw material, and the cellulose powder obtained by such a wet grinding process is cotton powder. The cotton powder has low content of impurities such as lignin and ash, so that the prepared medical dressing has low allergy risk, and the applicability of the medical dressing can be increased.
The medical dressing of the present disclosure includes modified cellulose, and the modified cellulose is formed by cationizing cellulose powder having a crystallinity of 0 to 0.5. Specifically, cationizing the cellulose powder may include the following steps. First, cellulose powder is dissolved in an alkaline solution. Then, the quaternary ammonium salt is added to the alkaline solution, and the alkaline solution is heated. Finally, the alkaline solution is dried to form the modified cellulose.
In detail, the milled cellulose powder may be first dissolved in an alkaline solution as a catalytic environment to promote the subsequent cationic substitution reaction. Since the cellulose powder is ground to have low crystallinity, the cellulose powder can be uniformly distributed in an alkaline solution of low concentration. Therefore, an alkaline solution having an alkaline substance concentration of less than 10 wt% can be selected to perform the above cationic substitution reaction, so as to reduce the use and residue of the chemical solvent. Preferably, the alkaline solution can be, for example, a sodium hydroxide solution having a concentration of between 5 wt% and 10 wt%.
Next, a quaternary ammonium salt including a cationic group is added to the above-mentioned alkaline solution and the alkaline solution is heated so that the cationic group of the quaternary ammonium salt replaces the hydroxide functional group of the cellulose powder. In some embodiments, the quaternary ammonium salt may include 3-chloro-2-hydroxypropyltrimethylammonium chloride, the activity of which may increase the efficiency of cationization. In this manner, cationic substitution reactions can be achieved using low concentrations of quaternary ammonium salts. For example, the concentration of the quaternary ammonium salt in the alkaline solution may be between 6.0 wt% and 6.5 wt%. In some embodiments, the alkaline solution may be heated to 70 to 80 ℃ for 3 to 4 hours, and then subjected to a drying process to form the modified cellulose having cationic groups.
According to the above embodiments of the present disclosure, the cellulose powder is cationized to form the modified cellulose having cationic groups, so that the medical dressing material including the modified cellulose has a good bacteriostatic effect. Because the cellulose powder has low crystallinity, cationization between the cellulose powder and the modifying agent can be promoted, so that the substitution degree of the modified cellulose is increased, the modifying efficiency is improved, the use of the modifying agent and a chemical solvent is reduced, and the modifying cost is reduced.
In the following description, various measurements and evaluations will be made with respect to the modified cellulose of the present disclosure and medical dressings comprising the modified cellulose. Hereinafter, the features of the present disclosure will be described more specifically with reference to experimental example 1 and experimental example 2. Although the following embodiments are described, the materials used, the amounts and ratios thereof, the details of the processes, the flow of the processes, and the like may be appropriately changed without departing from the scope of the present disclosure. Therefore, the present disclosure should not be construed in a limiting sense by the embodiments described below.
< experimental example 1: evaluation of crystallinity of cellulose powder >
In the present experimental example, the cellulose raw material of each example was subjected to wet grinding, and the cellulose powder formed in each example and the unground cellulose raw material of comparative example were subjected to evaluation of crystallinity. Specifically, the crystallinity is obtained by measuring the diffraction intensity of a cellulose powder or a cellulose raw material by an X-ray diffraction analyzer and calculating by the following formula (3), wherein I 22.6 And I 18.5 The diffraction intensities of the crystalline phase and the amorphous phase of the cellulose powder or the cellulose raw material, respectively, in X-ray diffraction.
The results of measuring the wet-grinding parameters and crystallinity of the cellulose raw materials of the examples and comparative examples are shown in table one.
Watch 1
Note 1: the weight of the zirconia beads was 200g
As can be seen from the Table I, the crystallinity of the unground cellulose material in the comparative example was greater than 0.5. In contrast, the crystallinity of the cellulose powder of each example was between 0 and 0.5 (although the crystallinity of example 4 was-0.05, the crystallinity was considered to be 0 in consideration of the error of the measurement by the instrument). Therefore, the cellulose powder of each example can have a suitable crystallinity after the cellulose raw material is physically wet-milled.
< experimental example 2: evaluation of degree of substitution of modified cellulose and inhibition of bacteria of medical dressing >
In the present experimental example, the cellulose powder of each example and the cellulose raw material of the comparative example were subjected to a modification process to evaluate the degree of substitution of the modified cellulose formed, and the same process was performed for each modified cellulose to evaluate the bacteriostatic effect of the medical dressing formed. Specifically, the substitution degree of the modified cellulose is measured by measuring the nitrogen content by an element analyzer, and the substitution degree of the cationic group is calculated by the following manner (4), where N% is the percentage of the nitrogen content in the modified cellulose.
On the other hand, strains of the control group and the experimental group (for example, staphylococcus aureus, pneumococcus, etc.) were cultured under the same conditions, and the medical dressings of the respective examples or comparative examples were put into the experimental group. After 18 to 24 hours of cultivation, the amounts of bacteria remaining in the control group and the experimental group were measured, and the bacteriostatic values of each example and comparative example were calculated using the following manner (5).
The results of measurements of the modification process parameters, the degree of substitution, and the bacteriostatic value of the medical dressing are shown in table two.
Watch two
As can be seen from table two, the cellulose raw material of the comparative example has high crystallinity, the substitution degree of the modified cellulose formed therefrom is less than 0.25, and the bacteriostatic values of the medical dressings including the modified cellulose of the comparative example are all less than 0. In contrast, the modified cellulose formed by the low-crystallinity cellulose powder of each example had a degree of substitution of 0.25 to 0.6, showing that each example had good modification efficiency. In addition, the cationization is carried out by the quaternary ammonium salt with lower concentration in each example, the substitution degree of the formed modified cellulose is larger than that of the modified cellulose in the comparative example 2 which is carried out by the cationization by the quaternary ammonium salt with higher concentration, and therefore, each example has lower modification cost. On the other hand, the medical dressing including the modified cellulose of each example had a bacteriostatic value between 85% and 100% against both staphylococcus aureus and diplococcus pneumoniae. That is, the medical dressing of each embodiment has a good bacteriostatic effect.
Through the verification of the above experimental examples, the medical dressing disclosed by the present disclosure may include modified cellulose with a suitable degree of substitution, which has a good bacteriostatic effect against various bacterial strains. The modified cellulose is formed from cellulose powder having low crystallinity, which can increase the modification efficiency and reduce the modification cost.
The foregoing outlines features of some embodiments so that those skilled in the art may better understand the aspects of the present disclosure. Those skilled in the art should appreciate that they may readily use the present disclosure as a basis for designing or modifying other processes and structures for carrying out the same purposes and/or achieving the same advantages of the embodiments introduced herein. Those skilled in the art should also realize that such equivalent constructions do not depart from the spirit and scope of the present disclosure, and that they may make various changes, substitutions, and alterations herein without departing from the spirit and scope of the present disclosure.
Claims (10)
1. A medical dressing comprising a modified cellulose having a cationic group, wherein the modified cellulose is obtained by cationizing a cellulose powder having a crystallinity of 0 to 0.5.
2. The medical dressing of claim 1, wherein said cationic groups of said modified cellulose have a degree of substitution between 0.25 and 0.6.
3. The medical dressing of claim 1, wherein the medical dressing has a bacteriostatic number between 85% and 100%.
4. The medical dressing of claim 1, wherein said cellulose powder having a crystallinity of between 0 and 0.5 is formed by wet grinding a cellulose material in a neutral aqueous solution.
5. The medical dressing of claim 4, wherein said wet grinding comprises grinding said cellulosic feedstock with a planetary ball mill and zirconia beads, wherein said zirconia beads have a diameter between 0.2 cm and 1.0 cm.
6. The medical dressing of claim 1, wherein said cellulose powder is cotton powder.
7. The medical dressing of claim 1, wherein cationizing the cellulose powder comprises:
dissolving the cellulose powder in an alkaline solution;
adding a quaternary ammonium salt to the alkaline solution;
heating the alkaline solution; and
and drying the alkaline solution to form the modified cellulose.
8. The medical dressing of claim 7, wherein said alkaline solution is a sodium hydroxide solution having a concentration between 5 wt.% and 10 wt.%.
9. The medical dressing of claim 7, wherein said quaternary ammonium salt is present in said alkaline solution at a concentration of between 6.0 wt.% and 6.5 wt.%.
10. The medical dressing of claim 7 wherein said quaternary ammonium salt is 3-chloro-2-hydroxypropyltrimethylammonium chloride.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| TW110106498A TWI798649B (en) | 2021-02-24 | 2021-02-24 | Medical dressing |
| TW110106498 | 2021-02-24 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN114949326A true CN114949326A (en) | 2022-08-30 |
Family
ID=82973150
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202110420483.0A Pending CN114949326A (en) | 2021-02-24 | 2021-04-19 | Medical dressing material |
Country Status (2)
| Country | Link |
|---|---|
| CN (1) | CN114949326A (en) |
| TW (1) | TWI798649B (en) |
Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101855246A (en) * | 2007-11-14 | 2010-10-06 | 花王株式会社 | Method for producing cellulose ether derivative |
| CN102268096A (en) * | 2011-07-07 | 2011-12-07 | 中科院广州化学有限公司 | Cationic cellulose with high substitution degree and preparation method and application thereof |
| CN102597007A (en) * | 2009-10-29 | 2012-07-18 | 花王株式会社 | Production method for cationic hydroxypropyl cellulose |
| CN102781966A (en) * | 2010-03-02 | 2012-11-14 | 花王株式会社 | Method for producing cationized cellulose and method for producing cationized hydroxyalkyl cellulose |
| TW201544127A (en) * | 2014-05-27 | 2015-12-01 | Taiwan Textile Res Inst | Manufacturing method of dressing |
| CN106758500A (en) * | 2016-12-20 | 2017-05-31 | 齐鲁工业大学 | A kind of method of the modified papermaking filler of utilization cationic cellulose derivative |
| CN110409164A (en) * | 2019-09-09 | 2019-11-05 | 苏州汇涵医用科技发展有限公司 | The preparation method of antibacterial cationic fiber cellulose fiber medical dressing |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109072552B (en) * | 2016-04-22 | 2022-03-18 | 菲博林科技有限公司 | Redispersed microfibrillated cellulose |
| CN110325552B (en) * | 2017-03-07 | 2022-03-04 | 花王株式会社 | Method for producing modified cellulose fiber |
| CN111587271B (en) * | 2017-11-06 | 2022-06-28 | 克宁克莱克合作侨兴公司 | Treatment of cellulose |
-
2021
- 2021-02-24 TW TW110106498A patent/TWI798649B/en active
- 2021-04-19 CN CN202110420483.0A patent/CN114949326A/en active Pending
Patent Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101855246A (en) * | 2007-11-14 | 2010-10-06 | 花王株式会社 | Method for producing cellulose ether derivative |
| CN102597007A (en) * | 2009-10-29 | 2012-07-18 | 花王株式会社 | Production method for cationic hydroxypropyl cellulose |
| CN102781966A (en) * | 2010-03-02 | 2012-11-14 | 花王株式会社 | Method for producing cationized cellulose and method for producing cationized hydroxyalkyl cellulose |
| CN102268096A (en) * | 2011-07-07 | 2011-12-07 | 中科院广州化学有限公司 | Cationic cellulose with high substitution degree and preparation method and application thereof |
| TW201544127A (en) * | 2014-05-27 | 2015-12-01 | Taiwan Textile Res Inst | Manufacturing method of dressing |
| CN106758500A (en) * | 2016-12-20 | 2017-05-31 | 齐鲁工业大学 | A kind of method of the modified papermaking filler of utilization cationic cellulose derivative |
| CN110409164A (en) * | 2019-09-09 | 2019-11-05 | 苏州汇涵医用科技发展有限公司 | The preparation method of antibacterial cationic fiber cellulose fiber medical dressing |
Also Published As
| Publication number | Publication date |
|---|---|
| TWI798649B (en) | 2023-04-11 |
| TW202233259A (en) | 2022-09-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| dos Santos et al. | Response surface methodology applied to the study of the microwave-assisted synthesis of quaternized chitosan | |
| Li et al. | Chitosan natural polymer material for improving antibacterial properties of textiles | |
| Mittal et al. | Effects of alkaline or liquid-ammonia treatment on crystalline cellulose: changes in crystalline structure and effects on enzymatic digestibility | |
| Yu et al. | One-pot green fabrication and antibacterial activity of thermally stable corn-like CNC/Ag nanocomposites | |
| CN108755127B (en) | Chitosan quaternary ammonium salt antibacterial fiber and preparation process thereof | |
| CN103691967B (en) | A kind of simple method for preparing of novel extensive nano-silver hydrosol | |
| Xu et al. | DDA (degree of deacetylation) and pH-dependent antibacterial properties of chitin nanofibers against Escherichia coli | |
| Ciolacu et al. | Enzymatic hydrolysis of different allomorphic forms of microcrystalline cellulose | |
| CN109295524B (en) | Preparation method of antibacterial shape memory fiber | |
| Sharma et al. | Superabsorbent nanocomposite from sugarcane bagasse, chitin and clay: synthesis, characterization and swelling behaviour | |
| CN103628306A (en) | Chitosan single guanidine hydrochloride loaded nanometer titanium dioxide compound and preparation method thereof | |
| CN108264569B (en) | Cellulose II type nanocrystalline particles and preparation method and application thereof | |
| JP2017535684A (en) | Polyester composite material, polyester composite fiber, production method and use thereof | |
| Jordan et al. | Lignin-containing cellulose nanofibers with gradient lignin content obtained from cotton gin motes and cotton gin trash | |
| Wang et al. | Synthesis and characterization of cinnamic acid conjugated N-(2-hydroxy)-propyl-3-trimethylammonium chitosan chloride derivatives: A hybrid flocculant with antibacterial activity | |
| Zope et al. | Isolation and characterization of cellulose nanocrystals produced by acid hydrolysis from Banana Pseudostem | |
| CN114949326A (en) | Medical dressing material | |
| CN103319750A (en) | Carboxymethyl chitosan quaternary ammonium salt/modified zirconium phosphate nanometer composite material | |
| Ono et al. | Characterization of solid-state structures, molar masses, and microfibril structures of cellulose in never-dried cotton fibers and ramie bast fibers | |
| Vasconcelos et al. | Chemically modified cellulose nanocrystals as polyanion for preparation of polyelectrolyte complex | |
| CN103012807A (en) | Preparation method and application of modified humic acid quaternary ammonium salt | |
| CN110746510B (en) | Method for simultaneously reducing relative crystallinity and thermal stability of starch | |
| Xiao et al. | Durably antibacterial cotton fabric prepared by a combination of betaine and carboxymethyl chitosan | |
| CN101497667A (en) | Method for preparing cellulose succinate in ion liquid | |
| Suprabawati et al. | Crosslinked CMC-urea hydrogel made from natural carboxymethyl cellulose (CMC) as slow-release fertilizer coating |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20220830 |